Mersana Therapeutics (MRSN) News Today $1.60 -0.14 (-8.05%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Mersana Therapeutics: We're About To Find Out If ADC Platform Is More TolerableDecember 19 at 8:59 AM | seekingalpha.comPromising Clinical Data and Valuation Support Mersana Therapeutics’ Buy RecommendationDecember 17, 2024 | markets.businessinsider.comXTX Topco Ltd Buys 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)XTX Topco Ltd raised its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 186.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,255 shares of the company'sDecember 13, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. increased its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 104.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 993,046 shareDecember 8, 2024 | marketbeat.comAtom Investors LP Sells 340,774 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Atom Investors LP lessened its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 93.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,661 shares of the compaDecember 6, 2024 | marketbeat.comVerition Fund Management LLC Buys 1,292,200 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Verition Fund Management LLC lifted its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 11,695.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,303,249 shares of the company's stock after acqDecember 6, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued aDecember 3, 2024 | marketbeat.comAcuta Capital Partners LLC Has $2.27 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)Acuta Capital Partners LLC cut its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 27.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,200,000 shares of the companyNovember 28, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for MRSN EarningsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for Mersana Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.5November 18, 2024 | marketbeat.comWedbush Predicts Stronger Earnings for Mersana TherapeuticsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Analysts at Wedbush increased their FY2024 earnings estimates for Mersana Therapeutics in a report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.66) per share forNovember 18, 2024 | marketbeat.comBuy Rating for Mersana Therapeutics: Anticipated XMT-1660 Data as Key CatalystNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics transferred with Buy rating at CitiNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Coverage Initiated by Analysts at CitigroupCitigroup began coverage on shares of Mersana Therapeutics in a research note on Friday. They issued a "buy" rating and a $5.00 price objective on the stock.November 15, 2024 | marketbeat.comMersana Therapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)November 15, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deMersana Therapeutics Shares Climb 23% After 3Q Results Beat EstimatesNovember 13, 2024 | marketwatch.comThis Particular Biotech Stock Is Soaring On Two Key AnnouncementsNovember 13, 2024 | theglobeandmail.comMersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comMersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comMersana Therapeutics (MRSN) to Release Earnings on WednesdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comMersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024November 6, 2024 | globenewswire.comSILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics IncOctober 15, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rOctober 14, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Alejandra Carvajal Sells 5,598 SharesOctober 8, 2024 | insidertrades.comMersana Therapeutics, Inc. (NASDAQ:MRSN) CFO Sells $16,178.00 in StockOctober 8, 2024 | insidertrades.comMersana Therapeutics (NASDAQ:MRSN) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comBuy Rating on Mersana Therapeutics: Anticipated Upside from XMT-1660 Development and Market Valuation DisconnectOctober 1, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Acadian Asset Management LLCAcadian Asset Management LLC cut its holdings in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 84.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,506 shares of the company's stock after sellSeptember 21, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of "Moderate Buy" by BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, fSeptember 19, 2024 | marketbeat.comShort Interest in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Grows By 21.1%Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 10,280,000 shares, a growth of 21.1% from the August 15th total of 8,490,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is currently 8.4 days.September 15, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) CEO Sells $88,744.48 in StockSeptember 14, 2024 | insidertrades.comBuy Rating for Mersana Therapeutics: Promising ADC Developments and Strategic Market PositioningSeptember 14, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) CEO Martin H. Jr. Huber Sells 50,423 SharesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $1.76, for a total value of $88,744.48. Following the completion of the sale, the chief executive officer now owns 116,327 shares in the company, valued at $204,735.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.September 13, 2024 | marketbeat.comTruist Financial Releases a Buy Rating on Mersana Therapeutics (MRSN)September 11, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)September 5, 2024 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Given New $5.00 Price Target at CitigroupCitigroup reduced their target price on Mersana Therapeutics from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Tuesday.August 27, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, five have issuedAugust 25, 2024 | marketbeat.comQ3 2024 EPS Estimates for Mersana Therapeutics, Inc. Decreased by Analyst (NASDAQ:MRSN)Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2024 earnings estimates for Mersana Therapeutics in a research report issued to clients and investors on Tuesday, August 13th. Leerink Partnrs analyst J. Chang now expects that theAugust 15, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Releases Earnings Results, Misses Estimates By $0.02 EPSMersana Therapeutics (NASDAQ:MRSN - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). Mersana Therapeutics had a negative return on equity of 260.65% and a negative net margin of 352.01%. The firm had revenue of $2.30 million for the quarter, compared to analyst estimates of $8.72 million. During the same quarter in the previous year, the firm posted ($0.47) EPS. The business's revenue for the quarter was down 78.3% on a year-over-year basis.August 14, 2024 | marketbeat.comBuy Rating on Mersana Therapeutics: Advancing XMT-1660 Program and Promising Tolerability ProfileAugust 14, 2024 | markets.businessinsider.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 14, 2024 | finanznachrichten.deMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comMersana Therapeutics (NASDAQ:MRSN) Price Target Cut to $3.00 by Analysts at Robert W. BairdRobert W. Baird cut their target price on shares of Mersana Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Wednesday.August 14, 2024 | marketbeat.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 13, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comMersana Therapeutics is about to announce its earnings — here's what Wall Street expectsAugust 13, 2024 | markets.businessinsider.comMersana Therapeutics (MRSN) Scheduled to Post Earnings on TuesdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.August 7, 2024 | marketbeat.com Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss. Click Here to get the full details about Crypto’s Hidden Gem MRSN Media Mentions By Week MRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRSN News Sentiment▼0.850.61▲Average Medical News Sentiment MRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRSN Articles This Week▼22▲MRSN Articles Average Week Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COLL News Today SEPN News Today BCAX News Today ZYME News Today GYRE News Today PSTX News Today COGT News Today PAHC News Today NUVB News Today AVBP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRSN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRSN Stock Alerts